Mosapride citrate salt dihydrate
SIGMA/M2946
Synonym: 4-
CAS Number: 636582-62-2
Empirical Formula (Hill Notation): C21H25ClFN3O3 · C6H8O7 · 2H2O
Molecular Weight: 650.05
MDL Number: MFCD00874415
Linear Formula: C21H25ClFN3O3 · C6H8O7 · 2H2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | solid |
| InChI | 1S/C21H25ClFN3O3.C6H8O7.2 |
| InChI key | KVKIQHMTGSGTFO-UHFFFAOYSA |
| originator | Takeda |
| Quality Level | 100 ![]() |
| SMILES string | O.O.OC(=O)CC(O)(CC(O)=O)C |
| solubility | DMSO: ≥5 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | 5-HT4 receptor agonist and 5-HT3 receptor antagonist |
| Biochem/physiol Actions: | Mosapride is found effective against chronic gastritis, functional dyspepsia and gastro-oesophageal reflux disease. It is useful in treating many other symptoms associated with gastrointestinal disorders. Mosapride is known to improve digestive motility. |
| Features and Benefits: | This compound was developed by Takeda . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol | GHS05 |
| Signal word | Danger |
| Hazard statements | H318 |
| Precautionary statements | P280 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 41 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


